Cellivery is a biotech company developing innovative drug candidates with cell-/tissue-permeability based on Cellivery’s proprietary Therapeuticmolecule Systemic Delivery Technology (TSDT) Platform.
TSDT provides a powerful method to identify and validate potential therapeutic targets. Thus, Cellivery is developing TSDT applied cargos such as small molecules, antibody, and peptides to target rare diseases.
Cellivery’s therapeutic drug candidates are being developed for the prevention and treatment of life-threatening diseases, including cancer, inflammation, obesity, metabolic diseases, and neurodegenerative diseases.
The mission of Cellivery is to commercialize this unique and life-saving therapeutics to contribute to our society in aiding patients with hard-to-cure diseases.
Cellivery’s strategy is to collaborate with pharmaceutical and service companies globally. By collaborating, Cellivery can strengthen and further develop drug candidates and expedite the process of commercialization and marketing in order to help patients quickly and more effectively.
Cellivery is currently collaborating with global pharmaceutical companies, and CDMO/CROs to discover and develop novel biotherapeutics.